Estimates the balance of ischaemic benefit and bleeding harm from extending dual antiplatelet therapy beyond 12 months after PCI.
Sponsored
Advertising placement
Your privacy choices
MediCalc uses necessary cookies to provide secure accounts and essential website functions.
With your permission, we also use analytics cookies to understand how the website is used and
improve our clinical tools.